Ischemix is a privately-held pharmaceutical company that is developing novel cytoprotective compounds for serious neurological diseases and conditions.
Proof of concept in two preclinical models (focal and diffuse) of TBI. Significant improvement vs controls in sensorimotor and cognitive endpoints of learning and memory.
Proof of concept in two types of test subjects in a preclinical model of TBI. Significant reduction in br...
Ischemix is a privately-held pharmaceutical company that is developing novel cytoprotective compounds for serious neurological diseases and conditions.
Proof of concept in two preclinical models (focal and diffuse) of TBI. Significant improvement vs controls in sensorimotor and cognitive endpoints of learning and memory.
Proof of concept in two types of test subjects in a preclinical model of TBI. Significant reduction in brain lesion size, improvement in levels of brain metabolites, upregulation of mitochondrial energetics and reduction of reactive oxygen species in treated subjects versus controls.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.